Shares of Nevro Corp. have lost more than 70% of their value during the past year mainly because of softerthan-expected sales of the company’s spinal cord stimulation (SCS) systems for treating chronic pain. Management has largely blamed disruptions related to the COVID-19 pandemic, but Nevro’s one-year performance has lagged that of its med tech peers, leaving investors wondering whether there may be other forces at work.
Leave a Reply